Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL.
March 8, 2023 – Company announcement no. 3 |
On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen had entered into a merger agreement to combine by way of a statutory merger of the two companies (the "Combination") and thereby create a leading global biosolutions partner, with Novozymes as the continuing company for which Novozymes and Chr. Hansen jointly will develop a new name and brand (the "Combined Company"). Reference is made to Chr. Hansen's company announcement no. 13 of December 12, 2022.
Novozymes and Chr. Hansen will today through separate company announcements publish notices to convene their respective extraordinary general meetings to vote on the Combination.
As stated in Chr. Hansen's company announcement no. 13, 2022, each of the Novozymes Board of Directors and the Chr. Hansen Board of Directors support the Combination and unanimously recommend their respective shareholders to vote in favor of and adopt the Combination and the other proposals to be put forward by the Novozymes Board of Directors and the Chr. Hansen Board of Directors, respectively, in relation to the Combination.
Please see attachment.
CONTACT INFORMATION
Investor Relations
Anders Mohr Christensen
+45 2515 2364
dkamc@chr-hansen.com
Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Repurchase of Shares6.5.2024 18:30:00 CEST | Press release
Repurchase of Shares Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) has repurchased 46,070 of its own shares in the period from 29 April 2024 up to and including 3 May 2024 at an average price of €19.57. This is in accordance with the €15 million share buyback extension program originally announced on 27 October 2022, of which the period of execution was announced on 28 July 2023 to be extended by 12 months to 26 October 2024. The consideration of this purchase was €0.9 million. The total number of shares purchased under this program to date is 516,082 shares at an average price of €17.30 for a total consideration of €8.9 million. 2,278,464 shares were held in treasury as of 6 May 2024. Contact Details Flow Traders Ltd. Investors Eric Pan Phone: +31 20 7996180 Email: investor.relations@flowtraders.com About Flow Traders Flow Traders is a leading trading firm providing liquidity in multiple asset classes, covering all major exchanges. Founded in 2004, Flow Traders is a
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD6.5.2024 18:00:00 CEST | Press release
` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD). This recently launched program has reached the first step with the identification of 50 targets that have the potential to provide better treatment options for GA. These targets are derived from a cutting-edge CRISPR-based target discovery platform, which consists in a genome-wide screening in a phenotypic cellular assay reflective of GA disease. The preclinical team successfully already confirmed the potential of several of these targets across various relevant in vitro models. Next step is to continue the in vitro validation of the remaining identified targets and start their evaluation in GA ani
Appointment of Mary Ann Packo as CEO of Ipsos in North America6.5.2024 17:45:00 CEST | Press release
Appointment of Mary Ann Packo as CEO of Ipsos in North America Paris, New York - May 6, 2024 - Ipsos, one of the world's leading market research companies, is pleased to announce the appointment of Mary Ann Packo, effective today, as CEO of Ipsos in North America. Reporting to Ben Page, CEO of Ipsos, she joins the Group Management Committee. Mary Ann Packo has been working in the market research industry for over 25 years. She has extensive international experience, particularly in the field of brand building, marketing, advertising, consumer research, digital measurement and advisory services. Prior to joining Ipsos, Mary Ann was a Senior Partner at Hypothesis Group, a premium insights, strategy, and design agency. She began her career in the United States, before moving to Paris in 1995 as Executive Director of a joint venture dedicated to studies for Consumer Goods companies, and whose two shareholders were NFO, one of the leading American marketing research companies, and Ipsos. Ba
Coface records a very good start to the year with a net income of €68.4m, up 11.9%6.5.2024 17:36:00 CEST | Press release
Coface records a very good start to the year with a net income of €68.4m, up 11.9% Paris, 6 May 2024 – 17.35 Turnover: €464m, down -1.6% at constant FX and perimeterTrade credit insurance premiums decreased by -3.3%; growth in client activities was nil at the start of the year, after a negative H2-23Client retention still high (93.8%) but down from records; pricing effect remained negative (-1.3%)Double-digit growth in business information (+21.6% at constant FX) and debt collection (+24.1%); factoring down by -6.3%Net loss ratio at 35.8%, improved by 4.9 ppts; net combined ratio at 63.1%, improved by 3.2 pptsGross loss ratio at 33.2%, improved by 7.5 ppts with stable opening year reserving and high reserve releasesNet cost ratio up by 1.6 ppt to 27.3%, reflecting lower revenues and continued investments partially offset by better product mixNet income (group share) at €68.4m, up +11.9% compared to Q1-23Annualised RoATE1 at 14.8% Unless otherwise indicated, change comparisons refer to
Holding(s) in Company6.5.2024 17:25:00 CEST | Press release
Reykjavik, May 06, 2024 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:Amaroq Minerals Ltd.1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuerX2. Reason for the notification (please mark the appropriate box or boxes with an “X”)An acquisition or disposal of voting rightsXAn acquisition or disposal of financial instrumentsAn event changing the breakdown of voting rightsOther (please specify):3. Details of person subject to the notification obligationNameArion banki hf.City and country of registered office (if applicable)Reykjavik, Iceland4. Full name of shareholder(s) (if different from 3.)NameCity and country of registered office (if applicable)5. Date on which the threshold was crossed or reached:04 April 20246. Date on which issuer notified (DD/MM/YYYY):03 May 20247.